{"product_id":"ascendishealth-five-forces-analysis","title":"Ascendis Health Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAscendis Health faces moderate buyer power and high competitive rivalry as it navigates price-sensitive payers and rapid biotech innovation, while supplier leverage and regulatory hurdles add measurable strain; substitutes and new entrants pose evolving threats tied to novel therapies and partnerships.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Ascendis Health’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of API Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAscendis Health depends on a small set of API manufacturers, mainly in India and China, sourcing over 70% of key active ingredients from these regions as of 2025; that concentration raises supply risk. \u003c\/p\u003e\n\u003cp\u003eDisruptions or export curbs in those countries or a 10–25% raw-material price swing seen in 2023–24 could raise COGS materially. \u003c\/p\u003e\n\u003cp\u003eWith few certified vendors for some inputs, Ascendis has limited price leverage and faces supplier-driven margin pressure. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet strict South African Health Products Regulatory Authority (SAHPRA) and WHO Good Manufacturing Practice standards, shrinking eligible vendors and raising supplier leverage over Ascendis Health.\u003c\/p\u003e\n\u003cp\u003eCompliance reduces supplier pool by an estimated 40–60% in pharma sectors; certified suppliers charge 5–15% premiums for proven quality and traceability.\u003c\/p\u003e\n\u003cp\u003eSwitching costs are high: re‑certification audits take 6–12 months and can cost $50k–$200k, entrenching compliant suppliers’ bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Currency Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBecause Ascendis Health imports key active pharmaceutical ingredients, supplier power rises as the South African Rand fell about 14% vs the US Dollar in 2023–2024, forcing suppliers to pass FX costs through price increases of 8–12% on average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Ingredient Scarcity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of proprietary or seasonally limited ingredients for Ascendis Healths consumer and animal health divisions command strong leverage; few alternatives match required efficacy, letting suppliers set prices and 8–14 week lead times during peak demand.\u003c\/p\u003e\n\u003cp\u003eThis concentrated sourcing risk contributed to a 2024 COGS uptick of ~6% year-over-year in the consumer segment and forced spot purchases that raised input costs by ~10% in Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLimited vendors: top 3 suppliers supply \u0026gt;70% of niche inputs\u003c\/li\u003e\n\u003cli\u003eLead times: typical 8–14 weeks, extendable to 20+ weeks\u003c\/li\u003e\n\u003cli\u003ePrice impact: spot premiums ~10% during 2024 peaks\u003c\/li\u003e\n\u003cli\u003eOperational risk: 6% rise in consumer COGS in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistical Integration Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsuppliers offering integrated logistics and reliable cold-chain management hold outsized leverage over ascendis health because setting up independent routes costs upfront adds to per-dose delivery expenses per industry benchmarks increasing vendor dependency.\u003e\n\u003cpconsequently primary vendors with established networks can extract better terms contract durations higher minimums or price premia of ascendis faces material switching costs and clinical-supply risk.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh setup cost: USD 5–15m\u003c\/li\u003e\n\u003cli\u003eDelivery cost uplift: 20–30%\u003c\/li\u003e\n\u003cli\u003eSupplier price premium: 3–7%\u003c\/li\u003e\n\u003cli\u003eRely on cold-chain capacity for biologics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pconsequently\u003e\u003c\/psuppliers\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: Top-3 \u0026gt;70% share, certification costs and FX lift COGS +6% in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis Health faces high supplier power: top 3 vendors supply \u0026gt;70% of niche APIs, certified suppliers charge 5–15% premiums, and re‑certification takes 6–12 months costing $50k–$200k, raising switching costs; FX moves (Rand −14% vs USD in 2023–24) and 8–14 week lead times pushed 2024 consumer COGS +6% and spot premiums ~10%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 supplier share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified supplier premium\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRe-certification time\/cost\u003c\/td\u003e\n\u003ctd\u003e6–12 months \/ $50k–$200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRand vs USD (2023–24)\u003c\/td\u003e\n\u003ctd\u003e≈−14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 consumer COGS change\u003c\/td\u003e\n\u003ctd\u003e+6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpot premium 2024 peaks\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces for Ascendis Health analyzing competitive rivalry, supplier and buyer power, threat of substitutes and new entrants, and identifying disruptive threats and protective market dynamics to inform strategic positioning and valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Ascendis Health—quickly gauge competitive pressure and strategic risks to guide M\u0026amp;A, pricing, and expansion decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance of Retail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMajor retail groups Clicks Group (3 2024 stores) and Dis-Chem (pre-IPO 170+ stores by 2024) dominate South Africa’s pharmacy retail, giving them strong leverage to demand discounts up to mid‑teens percent and extended payment terms in vendor reports; shelf placement and promo support are routinely traded for price concessions.\u003c\/p\u003e\n\u003cp\u003eAscendis Health must balance margin pressure with access—losing prime shelf space would cut mass‑market reach for brands that drove R3.2bn revenue in 2024—so contract negotiations and targeted co‑funded promotions are critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState Procurement and Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe South African government buys pharma via large public-health tenders and accounted for about 40% of national medicine spend in 2024, giving it strong bargaining power to push prices down on bulk contracts.\u003c\/p\u003e\n\u003cp\u003eBecause tenders award large volumes, buyers can demand steep discounts; public-sector pricing pressure compressed margins across local suppliers to single-digit EBITDA in 2024.\u003c\/p\u003e\n\u003cp\u003eLosing one major government contract can cut a pharma division’s revenue by 10–30% depending on product mix—so Ascendis Health faces high revenue concentration risk from state procurement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate Hospital Group Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge private hospital groups like Netcare and Mediclinic use centralized procurement to secure bulk discounts, cutting supplier margins; in 2024 Netcare’s group purchasing reportedly reduced drug spend by ~12% year-on-year, pressuring makers such as Ascendis.\u003c\/p\u003e\n\u003cp\u003eThe hospitals’ ability to switch to generics and local suppliers raises buyer power: Mediclinic's tender wins show generic substitution rates above 30% in key therapeutic classes, intensifying price competition for Ascendis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Consumer Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn consumer health, brand loyalty often yields to price and availability, so customers switch vitamins or supplements freely with no financial or functional penalty.\u003c\/p\u003e\n\u003cp\u003eThis forces Ascendis Health to spend on marketing and competitive pricing; global supplement sales hit $155bn in 2024 and US retail price promotions rose 12% YoY, pressuring margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow switching costs → higher churn\u003c\/li\u003e\n\u003cli\u003e2024 global supplement market $155bn\u003c\/li\u003e\n\u003cli\u003eUS promo intensity +12% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eRequires sustained marketing spend, margin compression\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in Local Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising inflation and 2024 real wage declines in South Africa pushed households toward cheaper healthcare; generics now account for ~60% of private-sector volumes, increasing price pressure on Ascendis Health.\u003c\/p\u003e\n\u003cp\u003eBuyers compare prices online and through pharmacies; 2025 surveys show 47% of patients prioritize cost over brand, so manufacturers must prove quality to keep premiums.\u003c\/p\u003e\n\u003cp\u003eManufacturers face margin squeeze: a 5–8% average price discount by retailers in 2024 forced tighter gross margins across the sector.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics ~60% of private volumes\u003c\/li\u003e\n\u003cli\u003e47% of patients prioritize cost (2025 survey)\u003c\/li\u003e\n\u003cli\u003eRetailer discounts 5–8% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetailer leverage forces Ascendis into margin trade‑offs: discounts, promos, shelf access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor retailers (Clicks ~3650 stores 2024; Dis-Chem 170+ by 2024) and public tenders (~40% of medicine spend 2024) give buyers high leverage, forcing mid‑teens discounts, 5–8% retailer price cuts (2024) and margin squeeze; generics ~60% private volumes and 47% of patients prioritize cost (2025), so Ascendis must trade margin for shelf access and co‑funded promos.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetailer stores\u003c\/td\u003e\n\u003ctd\u003eClicks 3650; Dis‑Chem 170+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic spend\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetailer discounts\u003c\/td\u003e\n\u003ctd\u003e5–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost‑first patients\u003c\/td\u003e\n\u003ctd\u003e47% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAscendis Health Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Ascendis Health Porter’s Five Forces analysis you'll receive after purchase—no placeholders or mockups. It is the professionally written, fully formatted document ready for immediate download and use the moment you buy. The content covers competitive rivalry, supplier and buyer power, threat of substitutes, and barriers to entry with actionable insights. What you see is what you get—instantly accessible upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747229086073,"sku":"ascendishealth-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ascendishealth-five-forces-analysis.png?v=1772196267","url":"https:\/\/matrixbcg.com\/products\/ascendishealth-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}